A new targeted cancer drug, Daraxonrasib, has shown promising results in treating pancreatic cancer during Phase-3 clinical trials.
WHAT’S THE NEWS?
• A new anti-cancer drug called Daraxonrasib has shown encouraging results in pancreatic cancer treatment.
• The drug performed well in Phase-3 clinical trials for patients with KRAS-mutated cancers.
• Scientists believe it may improve survival rates in one of the deadliest forms of cancer.
KEY POINTS
• Pancreatic cancer is among the most difficult cancers to treat.
• The drug targets KRAS mutations responsible for uncontrolled cell growth.
• Clinical trials showed tumor shrinkage and delayed disease progression.
• The treatment is considered a targeted therapy approach.
• Researchers are optimistic about future applications in other cancers as well.
HOW IT WORKS 1. Cancer cells often contain KRAS gene mutations.
2. These mutations trigger uncontrolled cell division.
3. Daraxonrasib blocks abnormal KRAS protein activity.
4. This slows tumor growth and may shrink cancer cells.
5. Targeted therapy causes less damage to healthy cells compared to chemotherapy.
EXAMPLES
• Pancreatic cancer has a low survival rate globally.
• Similar targeted therapies are used in lung cancer and melanoma.
• Precision medicine is increasingly used in oncology treatment worldwide.
WHY IT MATTERS
• Pancreatic cancer is a major public health challenge.
• Advances in targeted therapy improve personalized medicine.
• Reduces dependence on highly toxic chemotherapy.
• Supports innovation in biotechnology and pharmaceutical research.
• Important for understanding cancer genetics and modern healthcare.
UPSC PRELIMS FOCUS
• Basics of cancer and mutations.
• KRAS mutation and targeted therapy.
• Difference between chemotherapy and immunotherapy.
• Biotechnology applications in medicine.
UPSC MAINS FOCUS
GS Paper 3: Science & Technology – Biotechnology in healthcare.
GS Paper 2: Public Health and access to healthcare.
Essay Topics: Role of biotechnology in improving human life.
THE BIG QUESTION
“Can precision medicine and targeted therapies transform cancer treatment into a more affordable and accessible healthcare solution for developing countries?”
SUMMARY
The development of Daraxonrasib marks an important step in cancer research and targeted medicine. Advances in biotechnology and precision therapy may significantly improve survival rates and redefine future cancer treatment strategies.